Login
Starling Oncology, Inc. logo

Starling Oncology, Inc.

starlingoncology.com

What Do They Do?

Provides community-based cancer care, including medical oncology, infusions, radiation therapy and specialty pharmacy services, for patients and health plans.

How Do They Make Money?

Health plans and other payors pay monthly per enrolled patient for managed cancer care; for fee-for-service care, insurers and patients are billed for care provided. Pharmacy benefit managers are billed when medications are ordered, and clinical-trial sponsors pay for procedures performed during a trial.

revenue
SegmentShareRevenue
Patient services
46%
FY2022: 66%
Specialty pharmacy
Sold outright

54%
Clinical trials & other
Usage-based
0.9%
FY2022: 2.5%

Who Are Their Customers?

Managed care organizations and other payors contract for oncology care for enrolled populations. Insurers and government programs pay for fee-for-service care; patients may also pay co-pays, while pharmaceutical companies and trial administrators pay for clinical research.

Do Revenues Turn Into Profits?

No. It lost $60.6M in FY2025.

Operating income, FY2025
−7% of revenue
▲ +40% (Loss) vs FY2024 (−$60.1M, −15%)
Net income, FY2025
−12% of revenue
▲ +6% (Loss) vs FY2024 (−$64.7M, −16%)
Free cash flow, FY2025
−6% of revenue
▲ +8% (Loss) vs FY2024 (−$30.3M, −8%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +24%
vs $136.6M in Q3 FY2025
Net income
▲ +5% (Loss)
vs −$16.5M in Q3 FY2025
Specialty Pharmacy share of revenue vs 55.6% in Q3 FY2025
  • Nov 5, 2026 Starling cut its 2026 revenue guidance range The company lowered its full-year revenue outlook from $650 to $670 million to $650 to $660 million.
  • Jul 28, 2026 The Oncology Institute changed its name to Starling Oncology The company also changed its stock ticker from TOI to STLN.

Growing. Revenue grew 2.5x in 4 years, from $203M in FY2021 to $502.7M in FY2025, about 25% a year.

A broader care-management role The latest report describes full delegation, in which the company takes on utilization management, network construction and claims adjudication in addition to providing care. The older report discussed evolving contracts to include acute-care use and non-employed oncologists.

Revenue over time
Patient services Specialty pharmacy Clinical trials & other Dispensary
$1B$500M$0

Who Do They Compete With?

Competes with American Oncology Network, U.S. Oncology Network, OneOncology, Evolent Health, Thyme Care, and OncoHealth

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support